MCM
LAB icon

MAI Capital Management’s Standard BioTools LAB Stock Holding History

MAI Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-718
Closed -$661 – 3514
2026
Q1 		$661 Buy
718
+418
+139% +$506 ﹤0.01% 4319
2025
Q4 		$384 Hold
300
– – ﹤0.01% 3905
2025
Q3 		$390 Hold
300
– – ﹤0.01% 3650
2025
Q2 		$360 Hold
300
– – ﹤0.01% 3810
2025
Q1 		$324 Sell
300
-343
-53% -$482 ﹤0.01% 3272
2024
Q4 		$1.13K Buy
+643
New +$1.2K ﹤0.01% 3166

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

MAI Capital Management's LAB Position: Q2 2026 in Review

MAI Capital Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 718 shares — an estimated $661 sold.

MAI Capital Management first reported a position in LAB in Q4 2024 and held it in 6 quarters. The position peaked at $1.13K in Q4 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • MAI Capital Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 718 Standard BioTools shares in Q2 2026, an estimated $661.
  • MAI Capital Management first reported a position in Standard BioTools in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Standard BioTools position peaked at $1.13K in Q4 2024.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.